Processing

Please wait...

Settings

Settings

1. IN201617034080 - CELASTROL AND DERIVATIVES FOR THE TREATMENT OF OBESITY

Office India
Application Number 201617034080
Application Date 05.10.2016
Publication Number 201617034080
Publication Date 10.02.2017
Publication Kind A
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
194
having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
195
having an amino group
197
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198
Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61K 31/19
A61K 31/194
A61K 31/198
Applicants THE CHILDRENS MEDICAL CENTER CORPORATION
Inventors MAZITSCHEK Ralph
ÖZCAN Umut
Priority Data 61/970839 26.03.2014 US
Title
(EN) CELASTROL AND DERIVATIVES FOR THE TREATMENT OF OBESITY
Abstract
(EN)
Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds or pharmaceutically acceptable salts or prodrugs thereof in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre obese obese or morbidly obese patient to induce weight loss reduce body fat reduce food intake improve glucose homeostasis prevent obesity or a combination thereof. The compounds can also be co administered with leptin or a leptin analog.